HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies

Trends in Immunology

Volumn 37, Issue 3, 2016, Pages 221-232

  de Taeye, Steven W ^a   Moore, John P ^b   Sanders, Rogier W ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROADLY NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; VACCINATION; VIRUS ENVELOPE; ANIMAL; DISEASE MODEL; EPITOPE MAPPING; HIV INFECTIONS; HUMAN; IMMUNOLOGY; PROTEIN MULTIMERIZATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPE MAPPING; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN MULTIMERIZATION;

EID: 84959517396     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.01.007     Document Type: Review

References (112)

1. Plotkin S. History of vaccination. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:12283-12287.
2. Doria-Rose N., et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 2009, 83:188-199.
3. Mascola J.R., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000, 6:207-210.
4. Parren P.W., et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 2001, 75:8340-8347.
5. + T cell decline and high viral load during acute infection. J. Virol. 2011, 85:4828-4840.
6. van Gils M.J., et al. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 2009, 23:2405-2414.
7. Shibata R., et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 1999, 5:204-210.
8. Hessell A.J., et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5:e1000433.
9. Hessell A.J., et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 15:951-954.
10. Kwong P.D., et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
11. Julien J-P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
12. Lyumkis D., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490.
13. Do Kwon Y., et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat. Struct. Mol. Biol. 2015, 22:522-531.
14. Lee J.H., et al. Model building and refinement of a natively glycosylated HIV-1 Env protein by high-resolution cryoelectron microscopy. Structure 2015, 23:1943-1951.
15. Pancera M., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014, 514:455-461.
16. Scharf L., et al. Broadly neutralizing antibody 8ANC195 recognizes closed and open states of HIV-1 Env. Cell 2015, 162:1379-1390.
17. Lee J.H., et al. Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nat. Commun. 2015, 6:8167.
18. Huang J., et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014, 515:138-142.
19. Falkowska E., et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014, 40:657-668.
20. Sok D., et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:17624-17629.
21. Julien J-P., et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:4351-4356.
22. Kong L., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 2013, 20:796-803.
23. Julien J.P., et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 2013, 9:e1003342.
24. Doria-Rose N.A., et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014, 509:55-62.
25. Sanders R.W., Moore J.P. HIV: a stamp on the envelope. Nature 2014, 514:437-438.
26. Moore P.L., et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 2006, 80:2515-2528.
27. Parren P.W.H.I., et al. HIV-1 antibody - debris or virion?. Nat. Med. 1997, 3:366-367.
28. Munro J.B., et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 2014, 346:759-763.
29. Guttman M., et al. Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nat. Commun. 2015, 6:6144.
30. Pugach P., et al. A native-like SOSIP.664 trimer based on a HIV-1 subtype B env gene. J. Virol. 2015, 89:3380-3395.
31. Harris A.K., et al. HIV-1 envelope glycoprotein trimers display open quaternary conformation when bound to the gp41 membrane-proximal external-region-directed broadly neutralizing antibody Z13e1. J. Virol. 2013, 87:7191-7196.
32. van Gils M.J., Sanders R.W. Broadly neutralizing antibodies against HIV-1: Templates for a vaccine. Virology 2013, 435:46-56.
33. Klein F., et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J. Exp. Med. 2012, 209:1469-14679.
34. Scheid J.F., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
35. Huang J., et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491:406-412.
36. Doria-Rose N.A., et al. A new member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J. Virol. 2015, 90:76-91.
37. Wu X., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
38. Walker L.M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
39. Walker L.M., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
40. Blattner C., et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 env trimers. Immunity 2014, 40:669-680.
41. Doores K.J., et al. Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. J. Virol. 2015, 89:1105-1118.
42. Derking R., et al. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog. 2015, 11:e1004767.
43. Sanders R.W., et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 2002, 76:7293-7305.
44. Scanlan C.N., et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-2 mannose residues on the outer face of gp120. J. Virol. 2002, 76:7306-7321.
45. Sok D., et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci. Transl. Med. 2014, 6:236ra63.
46. Pritchard L.K., et al. Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat. Commun. 2015, 6:7479.
47. Burton D.R., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
48. Wu X., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.
49. Liao H-X., et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013, 496:469-476.
50. Scheid J.F., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
51. Zhou T., et al. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 2015, 161:1280-1292.
52. Tran K., et al. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E738-E747.
53. Ruprecht C.R., et al. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J. Exp. Med. 2011, 208:439-454.
54. Stiegler G., et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 2001, 17:1757-1765.
55. Zwick M.B., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75:10892-10905.
56. Chen J., et al. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J. Virol. 2014, 88:1249-1258.
57. Kim A.S., et al. Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. PLoS Pathog. 2014, 10:e1004271.
58. Ringe R.P., et al. Influences on the design and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers. J. Virol. 2015, 89:12189-12210.
59. Go E.P., et al. Comparative analysis of the glycosylation profiles of membrane-anchored HIV-1 envelope glycoprotein trimers and soluble gp140. J. Virol. 2015, 89:8245-8257.
60. Go E.P., et al. Glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells identifies disulfide heterogeneity present in both proteins and differences in O-linked glycosylation. J. Proteome Res. 2014, 13:4012-4027.
61. Owens R. The human immunodeficiency virus type 1 envelope glycoprotein precursor acquires aberrant intermolecular disulfide bonds that may prevent normal proteolytic processing. Virology 1990, 179:827-833.
62. Pitisuttithum P., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 2006, 194:1661-1671.
63. Pitisuttithum P., et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J. Infect. Dis. 2003, 188:219-227.
64. Gilbert P., et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 2010, 202:595-605.
65. Pritchard L.K., et al. Structural constraints determine the glycosylation of HIV-1 envelope trimers. Cell Rep. 2015, 11:1604-1613.
66. Ringe R.P., et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:18256-18261.
67. Guttman M., et al. CD4-induced activation in a soluble HIV-1 Env trimer. Structure 2014, 22:974-984.
68. AlSalmi W., et al. A new approach to produce HIV-1 envelope trimers: both cleavage and proper glycosylation are essential to generate authentic trimers. J. Biol. Chem. 2015, 290:19780-19795.
69. Sundling C., et al. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J. Exp. Med. 2010, 207:2003-2017.
70. Forsell M.N.E., et al. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. J. Virol. 2005, 79:10902-10914.
71. Blish C.A., et al. Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J. Virol. 2010, 84:2573-2584.
72. Grundner C., et al. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 2005, 331:33-46.
73. Nkolola J.P., et al. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J. Virol. 2010, 84:3270-3279.
74. Phad G.E., et al. Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization. J. Immunol. 2015, 194:5903-5914.
75. Sanders R.W., et al. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015, 349:aac4223.
76. Binley J.M., et al. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 2002, 76:2606-2616.
77. Sanders R.W., et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 2002, 76:8875-8889.
78. Binley J.M., et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 2000, 74:627-643.
79. Klasse P.J., et al. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J. Virol. 2013, 87:9873-9885.
80. Khayat R., et al. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J. Virol. 2013, 87:9865-9872.
81. Julien J-P., et al. Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:11947-11952.
82. Wu X., et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 2006, 80:835-844.
83. Sanders R.W., et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013, 9:e1003618.
84. Garces F., et al. Molecular insights into the evolution of a potent family of HIV-1 broadly neutralizing antibodies. Immunity 2015, 43:1053-1063.
85. Guenaga J., et al. Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties. PLoS Pathog. 2015, 11:e1004570.
86. de Taeye S.W., et al. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell 2015, 163:1702-1715.
87. Sharma S.K., et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep. 2015, 11:539-550.
88. Georgiev I.S., et al. Single-chain soluble BG505.SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1 Env. J. Virol. 2015, 89:5318-5329.
89. Kovacs J.M., et al. Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:18542-18547.
90. Guttman M., Lee K.K. A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140. J. Virol. 2013, 87:11462-11475.
91. McGuire A.T., et al. HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 2014, 346:1380-1383.
92. Sliepen K., et al. Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology 2015, 12:82.
93. Crooks E.T., et al. Vaccine-elicited Tier 2 HIV-1 neutralizing antibodies bind to quaternary epitopes involving glycan-deficient patches proximal to the CD4 binding site. PLoS Pathog. 2015, 11:e1004932.
94. Bhiman J.N., et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat. Med. 2015, 21:1332-1336.
95. Haynes B.F., et al. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 2012, 30:423-433.
96. Dosenovic P., et al. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell 2015, 161:1505-1515.
97. Jardine J.G., et al. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 2015, 349:156-161.
98. McGuire A.T., et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 2013, 210:655-663.
99. Jardine J., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013, 340:711-716.
100. Hoot S., et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 2013, 9:e1003106.
101. van den Kerkhof T.L.G.M., et al. HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. Retrovirology 2013, 10:102.
102. Fera D., et al. Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:10275-10280.
103. Goo L., et al. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat. Med. 2014, 20:655-658.
104. van den Kerkhof T.L.G.M., et al. Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers. AIDS 2014, 28:1237-1240.
105. McGuire A.T., et al. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J. Virol. 2014, 88:2645-2657.
106. Sliepen K., et al. Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. Virology 2015, 486:116-120.
107. Andrabi R., et al. Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity 2015, 43:959-973.
108. Doyle-Cooper C., et al. Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J. Immunol. 2013, 191:3186-3191.
109. Kelsoe G., et al. Immune system regulation in the induction of broadly neutralizing HIV-1 antibodies. Vaccines 2014, 2:1-14.
110. Sliepen K., Sanders R.W. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. Expert Rev Vaccines 2016, Published online January 8, 2016. 10.1586/14760584.2016.1129905.
111. Go E.P., et al. Native conformation and canonical disulfide bond formation are interlinked properties of HIV-1 Env glycoproteins. J. Virol. 2015, Published online December 30, 2015. 10.1128/JVI.01953-15.
112. Malherbe D.C., et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virol. 2011, 85:5262-5274.